Pharmaceutical giant Eli Lilly just dropped $3. 25 billion upfront on a startup called Kelonia Therapeutics, with the potential to pay $7 billion total if everything goes right. The big idea? A treatment that turns your own immune cells into cancer fighters without the usual lab work. Instead of yan
San Diego’s science labs are mostly empty. About a third of the space sits unused, which is almost as high as it has ever been. The city’s rental rates are dropping and landlords offer more discounts, so some companies are stepping in. The latest data shows a split scene. Venture money is coming ba
OpenAI’s newest AI model, named after DNA pioneer Rosalind Franklin, isn’t built to write poems or plan dinner menus. Instead, it’s trained to dig through mountains of scientific data to help researchers find new medicines faster. Drug development usually takes over a decade, but this tool could cut
CareDx just decided to sell off one of its smaller businesses so it can double down on the parts that are actually making money. The company’s president once said the division being sold—Lab Products, which makes test kits used worldwide—operates differently from the rest of their business. That’s b
Science Corp isn't diving into brain surgery just for the thrill. The company plans to place a tiny sensor on a human brain during an already scheduled operation. The 520-electrode chip, no bigger than a pea, will rest on the brain's surface, recording activity without digging deep. This isn't a sci
Two biotech firms are trying to cash in on investor excitement around obesity drugs and disease-detecting technology. One company wants $533 million to develop weight-loss treatments, while another seeks $159 million to expand its diagnostic tools. Both plan to sell shares to the public soon, hoping
A Chinese biotech company in Suzhou has given an American firm the worldwide rights to create and sell six new RNA medicines aimed at a serious liver condition. The deal brings an upfront cash payment of $60 million and could grow to nearly $4. 5 billion if the medicines reach several key develop
Scientists have been working on making a special enzyme better at producing a form of vitamin D. This enzyme is a mix of different parts, like a custom-made tool. The usual way to improve such enzymes is to tweak small parts here and there. But this time, the team took a bigger picture approach. Th
ViroMissile, Inc. has welcomed Michael G. Wood as their new Chief Business Officer. This move is big news for the company, which is working on a new way to fight cancer using viruses. Wood's job will be to help the company grow, find money for projects, and make important deals. Wood has a lot of e
January 14, 2026, was a big day for tech funding. Investors put a lot of money into AI, robotics, and cybersecurity. Skild AI got $1. 4 billion to build a "brain" for robots. This brain can control different types of robots, like humanoids and drones. The company wants to make robots smarter and mor
